Gruss & Co., LLC Biogen Inc. Transaction History

Gruss & Co., LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 07, 2018	SELL	$293.51 - $383.83 $1.32 Million - $1.73 Million	-4,500 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $1.3 Million - $1.84 Million	-5,000 Reduced 52.63%	4,500 $1.23 Million
Q4 2017 Feb 12, 2018	BUY	$307.64 - $344.58 $153,820 - $172,290	500 Added 5.56%	9,500 $3.03 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $2.53 Million - $2.97 Million	9,000	9,000 $2.82 Million

1,049

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $26.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gruss & Co., LLC, based on Form 13F filings with the SEC.

Stay updated on Gruss & Co., LLC with notifications on news.